School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Pancreatology. 2018 Dec;18(8):954-961. doi: 10.1016/j.pan.2018.09.014. Epub 2018 Oct 1.
At present, pancreatic ductal adenocarcinoma (PDAC) is a fetal disease lack of effective prognostic and therapeutic methods resulting in high mortality. The Notch signaling has been demonstrated being up- or down-regulated in many cancers, but the effects in pancreatic ductal adenocarcinoma are still controversial. Moreover, the available cases in an individual study are of small samples. Therefore, it is essential to define the effect of Notch signaling in pancreatic ductal adenocarcinoma with larger samples.
Conducted from 6 eligible studies and 463 pancreatic ductal adenocarcinoma patients, this was the first meta-analysis to analyze the correlation between the Notch signal pathway and pancreatic ductal adenocarcinoma. All data were sourced from The National Center for Biotechnology Information, Web of Science and Cochrane. The articles which matched the inclusion criteria were included. All included data were analyzed and performed by Review Manager 5.3.
The results indicated that high expression of Notch signaling proteins was associated with poor overall survival of pancreatic ductal adenocarcinoma patients (pooled hazard ratio>2.00; P < 0.001). Moreover, poor survival was related to high expression of Notch3 (pooled hazard ratio: 2.05; confidence interval: 1.49-2.82; P < 0.001) and DLL4 (pooled hazard ratio: 2.13; confidence interval: 1.37-3.32; P < 0.001).
This meta-analysis supports that Notch signaling proteins may be available as prognostic factors for pancreatic ductal adenocarcinoma progression and patient survival. Higher expression of Notch signaling proteins indicated poor survival of pancreatic ductal adenocarcinoma patients. Targeting Notch signaling components, especially Notch3 protein, would be beneficial for therapies.
目前，胰腺导管腺癌（PDAC）是一种胎儿疾病，缺乏有效预后和治疗方法，导致死亡率高。 Notch 信号已被证明在许多癌症中上调或下调，但在胰腺导管腺癌中的作用仍存在争议。此外，个别研究中的可用病例样本量较小。因此，用更大的样本量来确定 Notch 信号在胰腺导管腺癌中的作用是至关重要的。
从 6 项符合条件的研究和 463 例胰腺导管腺癌患者中进行分析，这是首次对 Notch 信号通路与胰腺导管腺癌之间的相关性进行的荟萃分析。所有数据均来自美国国立生物技术信息中心、Web of Science 和 Cochrane。纳入符合纳入标准的文章。所有纳入的数据均由 Review Manager 5.3 进行分析和处理。
结果表明， Notch 信号蛋白高表达与胰腺导管腺癌患者总生存率差相关（合并危险比>2.00；P<0.001）。此外， Notch3（合并危险比：2.05；置信区间：1.49-2.82；P<0.001）和 DLL4（合并危险比：2.13；置信区间：1.37-3.32；P<0.001）的高表达与不良生存相关。
这项荟萃分析支持 Notch 信号蛋白可能作为胰腺导管腺癌进展和患者生存的预后因素。 Notch 信号蛋白的高表达表明胰腺导管腺癌患者的生存较差。靶向 Notch 信号成分，特别是 Notch3 蛋白，将有利于治疗。
